Cypherpunk Swings to $39.4M Profit on ZEC Rally; Leap Subsidiary Aligns with FDA on Phase 3 Trial
CYPH has more than doubled off its 52-week low of $0.232 on light trading volume (0.2× avg).
Summary
Cypherpunk Technologies reported Q2 2026 net income of $39.4 million, driven by a $46 million unrealized gain on its Zcash holdings, while its Leap Therapeutics subsidiary aligned with the FDA on a Phase 3 trial design for sirexatamab in colorectal cancer and began a strategic review to fund the program.
Updates
· Reuters — Cypherpunk announced a strategic review for sirexatamab, including potential partnerships or a spin-out, and R&D costs dropped after a clinical trial wrapped and headcount was cut.
Key Events · Earnings and Guidance · CYPH
-
Q2 Profit Driven by ZEC Rally
Net income of $39.4 million ($0.18 per diluted share) vs. a $16.6 million loss in Q2 2025, due to a $46.0 million unrealized gain on ZEC holdings as the price rose from $243.35 to $400.09.
-
ZEC Treasury Now $129.4 Million
Holdings increased to 323,394 ZEC (1.92% of circulating supply) at an average cost of $341.83, valued at $129.4 million as of June 30, 2026, against $7.6 million in cash.
-
FDA Alignment on Phase 3 Trial
Leap Therapeutics reached agreement with the FDA on a randomized, controlled Phase 3 trial for sirexatamab in DKK1-high second-line colorectal cancer, with ORR supporting accelerated approval and OS for full approval.
-
Phase 2 Data Published, Biomarker Validated
Publication in Clinical Cancer Research confirmed that baseline plasma DKK1 predicts sirexatamab benefit; in DKK1-high patients, ORR was 38% vs. 24% and median OS was not reached vs. 14.4 months.
Analysis · CYPH · Life Sciences
A dramatic swing to profitability marks Cypherpunk Technologies' Q2 2026, with net income reaching $39.4 million versus a $16.6 million loss a year ago. The entire gain stems from a $46.0 million unrealized gain on its Zcash (ZEC) treasury holdings, which surged from $243 to $400. Now holding 323,394 ZEC worth $129.4 million, the company's equity value is highly correlated to ZEC price movements, dwarfing its $7.6 million cash balance. Meanwhile, the Leap Therapeutics subsidiary achieved a major de-risking event: alignment with the FDA on a registrational Phase 3 trial for sirexatamab in a biomarker-defined colorectal cancer population, with a dual-endpoint design supporting both accelerated and full approval. However, Leap has initiated a strategic process to secure funding or a partner, signaling that Cypherpunk may not fund the expensive Phase 3 trial itself, which introduces uncertainty around dilution or asset separation. The combination of a volatile, crypto-driven earnings profile and a high-stakes biotech catalyst makes this a critical update for investors.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CYPH was trading at $0.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $72.4M. The 52-week trading range was $0.23 to $3.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.